AB0264 Comparison of drug survival, safety and doses of etanercept, infliximab and adalimumab in rheumatoid arthritis patients: thirteen years canadian clinical practice experience.

Abstract

BackgroundTNF-α inhibitors etanercept, infliximab and adalimumab have been used for more than 10 years to treat moderate to severe rheumatoid arthritis (RA). Different studies reported different drug survival rate for...